Castleark Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$67.6M Sell
73,478
-8,100
-10% -$8.21M 2.24% 10
2025
Q4
$87.7M Buy
81,578
+37,025
+83% +$35.4M 2.57% 6
2025
Q3
$34M Sell
44,553
-1,615
-3% -$1.2M 0.95% 22
2025
Q2
$36M Sell
46,168
-33,524
-42% -$26.1M 1.08% 20
2025
Q1
$65.8M Buy
79,692
+36,926
+86% +$30.7M 2.28% 13
2024
Q4
$33M Sell
42,766
-22,560
-35% -$18.7M 1.15% 20
2024
Q3
$57.9M Sell
65,326
-13,406
-17% -$12.1M 2.36% 9
2024
Q2
$71.3M Buy
78,732
+1,020
+1% +$816K 2.91% 6
2024
Q1
$60.5M Sell
77,712
-1,030
-1% -$733K 2.52% 9
2023
Q4
$45.9M Sell
78,742
-2,343
-3% -$1.37M 2.03% 12
2023
Q3
$43.6M Sell
81,085
-41,780
-34% -$21.5M 2.22% 10
2023
Q2
$57.6M Buy
122,865
+290
+0.2% +$122K 2.61% 8
2023
Q1
$42.1M Sell
122,575
-1,900
-2% -$641K 2.07% 13
2022
Q4
$45.5M Sell
124,475
-21,050
-14% -$7.46M 2.38% 8
2022
Q3
$47.1M Sell
145,525
-11,420
-7% -$3.62M 2.62% 5
2022
Q2
$50.9M Sell
156,945
-9,650
-6% -$2.9M 2.72% 6
2022
Q1
$47.7M Sell
166,595
-8,870
-5% -$2.28M 2.06% 12
2021
Q4
$48.5M Sell
175,465
-380
-0.2% -$96.3K 1.78% 15
2021
Q3
$40.6M Sell
175,845
-6,445
-4% -$1.59M 1.55% 16
2021
Q2
$41.8M Buy
182,290
+55,120
+43% +$11.1M 1.41% 22
2021
Q1
$23.8M Buy
127,170
+7,945
+7% +$1.55M 0.86% 30
2020
Q4
$20.1M Buy
119,225
+34,365
+40% +$5.13M 0.75% 36
2020
Q3
$12.6M Buy
+84,860
New +$13.1M 0.49% 48
2019
Q2
Sell
-161,966
Closed -$21M 375
2019
Q1
$21M Sell
161,966
-213,886
-57% -$26M 0.79% 31
2018
Q4
$43.5M Buy
375,852
+86,198
+30% +$9.63M 1.85% 7
2018
Q3
$31.1M Buy
+289,654
New +$29M 0.89% 21

Other funds holding LLY

Castleark Management's LLY Position: Q1 2026 in Review

Castleark Management reduced its Eli Lilly (LLY) stake by 9.9% in Q1 2026, selling an estimated $8.21M and leaving 73,478 shares worth $67.6M. The position accounts for 2.24% of the portfolio, ranked #10.

Castleark Management first reported a position in LLY in Q3 2018 and has held it in 26 quarters since. The position peaked at $87.7M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Castleark Management held 73,478 shares of Eli Lilly worth $67.6M as of Q1 2026.
  • Castleark Management sold 8,100 Eli Lilly shares in Q1 2026, an estimated $8.21M.
  • Eli Lilly made up 2.24% of Castleark Management's portfolio in Q1 2026, its #10 holding.
  • Castleark Management first reported a position in Eli Lilly in Q3 2018 and has held it in 26 quarters since.
  • Castleark Management's Eli Lilly position peaked at $87.7M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.